David B Badesch

Summary

Publications

  1. doi request reprint Diagnosis and assessment of pulmonary arterial hypertension
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80045, USA
    J Am Coll Cardiol 54:S55-66. 2009
  2. ncbi request reprint Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress
    Robert A Quaife
    Cardiac Imaging, Division of Cardiology, University of Colorado Health Sciences Center, B 120, 4200 East Ninth Avenue, Denver, Colorado 80262, USA
    Eur J Med Res 11:214-20. 2006
  3. ncbi request reprint Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Box C 272, 4200 E Ninth Ave, Denver, CO 80262, USA
    Chest 131:1917-28. 2007
  4. ncbi request reprint Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chest 126:35S-62S. 2004
  5. ncbi request reprint Sildenafil for pulmonary arterial hypertension associated with connective tissue disease
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Rheumatol 34:2417-22. 2007
  6. ncbi request reprint Prostanoid therapy for pulmonary arterial hypertension
    David B Badesch
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Am Coll Cardiol 43:56S-61S. 2004
  7. doi request reprint Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
    David B Badesch
    Department of Medicine, University of Colorado Denver, Denver, Colorado, USA
    J Rheumatol 36:2244-9. 2009
  8. ncbi request reprint Metastatic cancer while receiving continuous prostacyclin therapy
    Karen A Fagan
    Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, Pulmonary Hypertension Center, Denver, CO, USA
    Chest 128:619S-620S. 2005
  9. doi request reprint Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry
    David B Badesch
    Divisions of Pulmonary Sciences and Critical Care Medicine, and Cardiology, University of Colorado Denver, Denver, CO, USA
    Chest 137:376-87. 2010
  10. ncbi request reprint Pulmonary vascular manifestations of mixed connective tissue disease
    Todd M Bull
    Division of Pulmonary Sciences and Critical Care Medicine, Pulmonary Hypertension Center, University of Colorado School of Medicine, 4200 East Ninth Avenue, Box C 272, Denver, CO 80262, USA
    Rheum Dis Clin North Am 31:451-64, vi. 2005

Detail Information

Publications11

  1. doi request reprint Diagnosis and assessment of pulmonary arterial hypertension
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80045, USA
    J Am Coll Cardiol 54:S55-66. 2009
    ....
  2. ncbi request reprint Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress
    Robert A Quaife
    Cardiac Imaging, Division of Cardiology, University of Colorado Health Sciences Center, B 120, 4200 East Ninth Avenue, Denver, Colorado 80262, USA
    Eur J Med Res 11:214-20. 2006
    ..0001). Right ventricular RWS is significantly elevated in IPAH and may provide a useful quantitative monitoring tool in patients with IPAH to assess the benefit of different therapeutic interventions and provide prognostic information...
  3. ncbi request reprint Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Box C 272, 4200 E Ninth Ave, Denver, CO 80262, USA
    Chest 131:1917-28. 2007
    ..Due to the complexity of the diagnostic evaluation required and the treatment options available, referral of patients with PAH to a specialized center continues to be strongly recommended...
  4. ncbi request reprint Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chest 126:35S-62S. 2004
    ..Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center...
  5. ncbi request reprint Sildenafil for pulmonary arterial hypertension associated with connective tissue disease
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Rheumatol 34:2417-22. 2007
    ..The phosphodiesterase-5 inhibitor sildenafil citrate enhances vasodilatation, has antiproliferative effects, and is effective in the treatment of PAH. We examined the efficacy and safety of oral sildenafil in patients with PAH-CTD...
  6. ncbi request reprint Prostanoid therapy for pulmonary arterial hypertension
    David B Badesch
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Am Coll Cardiol 43:56S-61S. 2004
    ..In conclusion, though treatment with prostanoids is complicated by their generally short half-lives and complicated drug delivery systems, they continue to play an important role in the treatment of PAH...
  7. doi request reprint Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
    David B Badesch
    Department of Medicine, University of Colorado Denver, Denver, Colorado, USA
    J Rheumatol 36:2244-9. 2009
    ..v.) infusion in an uncontrolled open-label 3-year extension study following an initial randomized, controlled 12-week study...
  8. ncbi request reprint Metastatic cancer while receiving continuous prostacyclin therapy
    Karen A Fagan
    Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, Pulmonary Hypertension Center, Denver, CO, USA
    Chest 128:619S-620S. 2005
  9. doi request reprint Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry
    David B Badesch
    Divisions of Pulmonary Sciences and Critical Care Medicine, and Cardiology, University of Colorado Denver, Denver, CO, USA
    Chest 137:376-87. 2010
    ....
  10. ncbi request reprint Pulmonary vascular manifestations of mixed connective tissue disease
    Todd M Bull
    Division of Pulmonary Sciences and Critical Care Medicine, Pulmonary Hypertension Center, University of Colorado School of Medicine, 4200 East Ninth Avenue, Box C 272, Denver, CO 80262, USA
    Rheum Dis Clin North Am 31:451-64, vi. 2005
    ..This article focuses on the pulmonary vasculature manifestations of MCTD. We briefly discuss associations between MCTD and interstitial lung disease, pleural disease, and alveolar hemorrhage...
  11. ncbi request reprint Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics
    William T Abraham
    Department of Medicine, University of Colorado, School of Medicine, Denver, USA
    J Renin Angiotensin Aldosterone Syst 4:27-30. 2003
    ....